ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy: A meta-analysis

Wang, Dan; Wang, Lijuan; Zhang, Mingrui; Li, Ping; Zhang, Qinghua; Bao, Kun*广州中医药大学
Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries2023-3-3DOI: 10.1097/MD.0000000000032918
11阅读
引用收藏
分享

摘要

Background:Idiopathic membranous nephropathy (IMN) is a noninflammatory autoimmune glomerulonephropathy. Based on the risk stratification for disease progression, conservative nonimmunosuppressive and immunosuppressive therapy strategies have been recommended. However, there remains challenges. Therefore, novel approaches to treat IMN are needed. We evaluated the efficacy of Astragalus membranaceus (A membranaceus) combined with supportive care or immunosuppressive therapy in the treatment of moderate-high risk IMN. Methods:We comprehensively searched PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure, the Database for Chinese Technical Periodicals, Wanfang Knowledge Service Platform, and SinoMed. We then performed a systematic review and cumulative meta-analysis of all randomized controlled trials assessing the two therapy methods. Results:The meta-analysis included 50 studies involving 3423 participants. The effect of A membranaceus combined with supportive care or immunosuppressive therapy is better than that of supportive care or immunosuppressive therapy along in regulating for improving 24 hours urinary total protein (MD = -1.05, 95% CI [-1.21, -0.89], P = .000), serum albumin (MD = 3.75, 95% CI [3.01, 4.49], P = .000), serum creatinine (MD = -6.24, 95% CI [-9.85, -2.63], P = .0007), complete remission rate (RR = 1.63, 95% CI [1.46, 1.81], P = .000), partial remission rate (RR = 1.13, 95% CI [1.05, 1.20], P = .0004). Conclusions:Adjunctive use of A membranaceus preparations combined with supportive care or immunosuppressive therapy have a promising treatment for improving complete response rate, partial response rate, serum albumin, and reducing proteinuria, serum creatinine levels compared to immunosuppressive therapy in people with MN being at moderate-high risk for disease progression. Given the inherent limitations of the included studies, future well-designed randomized controlled trials are required to confirm and update the findings of this analysis.

学科与关键词

关键词
Astragalus membranaceusChinese medicineIdiopathic membranous nephropathymeta-analysissystematic review
相关
加载中…
  • Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis
    You, Lu; Ye, Peiyi; Xiao, Guanqing; Liang, Jiabao; Kong, Yaozhong*Turkish Journal Of Medical Sciences, 2021, 51(6): 2870-2880.被引 2
  • The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy --protocol of a multicenter, randomized control trial (SQ-AUTUMN)
    Li, Chuang; Shan, Wenjun; Liang, Xing; Zhang, Qinghua; Qin, Xindong; Jiang, Sha; Hong, Xiaofan; Wang, Lijuan; Li, Ping; Gu, Haowen; Wang, Yi; Bao, Kun*BMC Complementary Medicine and Therapies, 2023, 23(1): 134.
  • Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy
    Liang, Jinxiu; Hao, Wenke; Xia, Fangxiao; Zhao, Zhi; Wu, Yanhua; Yu, Feng; Hu, Wenxue; Fang, Xiaowu; Liu, Wei*RENAL FAILURE, 2023, 45(1): 2212081.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
发表日期
2023-03-03
卷期
第 102 卷, 第 9 期
DOI
10.1097/MD.0000000000032918
语言
ENGLISH
成果收录
SCIE
资助标注
Natural Science Foundation of China [81974565]; Specific Fund of State Key Laboratory of Dampness Syndrome of Chinese Medicine [SZ2021ZZ36, SZ2021ZZ09]; Special Foundation of The 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund [2020B1212030006]; Guangdong province science and technology plan project [202102010212]

作者

  • W

    Wang, Dan (第一作者)

    2 · guangzhou univ chinese med

  • W

    Wang, Lijuan

    2 · guangzhou univ chinese med

查看全部 6 位作者收起作者
  • Z

    Zhang, Mingrui

    2 · guangzhou univ chinese med

  • L

    Li, Ping

    2 · guangzhou univ chinese med

  • Z

    Zhang, Qinghua

    2 · guangzhou univ chinese med

  • B

    Bao, Kun (通讯)

    2 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417